摘要
随着免疫检查点抑制剂(ICI)在临床的广泛应用, 其导致血栓事件的风险也随之增加, 且与不良生存率相关。有些研究认为ICI治疗可能导致肿瘤患者血栓事件发生风险增加, 但其相关性至今仍有争议, 发生率和危险因素也有较大差异。血栓事件的高风险肿瘤类型主要是肺、皮肤和泌尿生殖系统的恶性肿瘤, 血栓事件的临床类型主要为肺栓塞、心肌梗死和深静脉血栓形成, 血栓事件发生后的病死率较高。目前尚无ICI相关血栓风险的管理指南和共识, 本文就ICI与血栓事件的相关性、发生率、危险因素、发病机制、预防与治疗进行简要综述, 以期提高临床对这类不良反应的认识。
With the widespread clinical use of immune checkpoint inhibitors(ICIs),the risk of thrombotic events has also increased,which is related to the poor survival rate.Most studies indicate that ICIs treatment may increase the risk of thrombotic events in tumor patients,but the correlation is still controversial.The incidence and risk factors of thrombotic events are various in different studies.Patients with malignant tumors of lung,skin,and genitourinary system are at high risk of thrombotic events.The clinical types of thrombotic events are mainly pulmonary embolism,myocardial infarction,and deep vein thrombosis.The mortality rate in patients with thrombotic events is high.At present,there are no guidelines or consensus on the management of thrombosis risk related to ICIs.To improve the understanding of these adverse effects in clinic,this article reviews the correlation between ICIs and thrombotic events,and the incidence,risk factors,pathogenesis,prevention,and treatment of relevant thrombotic events.
作者
叶璇
尤玉芳
高菲菲
许璇
翟青
Ye Xuan;You Yufang;Gao Feifei;Xu Xuan;Zhai Qing(Department of Pharmacy,Fudan University Shanghai Cancer Center,Shanghai 200032,China)
出处
《药物不良反应杂志》
CSCD
2023年第3期172-177,共6页
Adverse Drug Reactions Journal
基金
上海申康医院发展中心临床三年行动计划资助项目(SHDC2020CR3085B)
上海申康医院发展中心医企融合创新支撑技能培训专项(SHDC2022CRS029)
上海市"医苑新星"青年医学人才培养资助计划―临床药师项目(沪卫人事[2021]99号)。
